【24h】

Immunosuppression in islet transplantation.

机译:胰岛移植中的免疫抑制。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Islet transplantation can temporarily cure type 1 diabetes mellitus (T1DM) but requires simultaneous immunosuppression to avoid allograft rejection. In this issue of the JCI, Monti et al. report that immune conditioning via use of the Edmonton protocol - a treatment approach in which T1DM patients infused with pancreatic islets from multiple cadaveric donors simultaneously receive immunosuppressive drugs - results in lymphopenia that is associated with elevated serum levels of the homeostatic cytokines IL-7 and IL-15, which causes in vivo expansion of the autoreactive CD8(+) T cell population (see the related article beginning on page 1806). Reemergence of autoreactivity is likely the main culprit underlying long-term islet graft failure, and new strategies will need to be tested to circumvent this homeostatic expansion and recurrent autoreactivity.
机译:胰岛移植可以暂时治愈 1 型糖尿病 (T1DM),但需要同时进行免疫抑制以避免同种异体移植排斥反应。在本期 JCI 中,Monti 等人报告说,通过使用埃德蒙顿方案进行免疫调节 - 一种治疗方法,其中输注来自多个尸体供体的胰岛的 T1DM 患者同时接受免疫抑制药物 - 导致淋巴细胞减少,这与稳态细胞因子 IL-7 和 IL-15 的血清水平升高有关,这会导致自身反应性 CD8(+) T 细胞群的体内扩增(参见第 1806 页开始的相关文章)。 自身反应性的重新出现可能是长期胰岛移植失败的罪魁祸首,需要测试新的策略来规避这种稳态扩张和复发性自身反应性。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号